2 Top Stocks to Buy and Hold for the Long Term

Novartis demonstrated resilience through a patent cliff, reporting Q3 revenue of $13.9 billion (up 8% YoY) and EPS of $2.25 (up 9% YoY), supported by a diversified pipeline (10 products >$1B as of Sept. 30) and recent launches such as Fabhalta; the company also maintains a 28-year dividend increase streak and a forward yield of ~3%. Shopify is enjoying strong momentum — the stock is up roughly 50% this year as the company grew share in its e‑commerce niche to ~12% by end-2024 (from 10% a year earlier), has returned to profitability in 3 of the last 4 quarters after divesting logistics, and benefits from high switching costs and expanding merchant services.

Analysis

Market structure: Novartis (NVS) benefits as a defensive large-cap pharma with a 3% forward yield and 10+ diversified products generating >$1bn each, which cushions Entresto patent erosion; generics suppliers and pure-play HF/CHF franchises are the direct losers. Shopify (SHOP) is a winner in merchant SaaS/commerce tooling — market share rose to 12% (2024) from 10% (2023) — increasing its pricing power to upsell services while marketplace competitors (some payments/logistics vendors) face margin pressure.

Risk assessment: Tail risks include regulatory/label setbacks or adverse Phase III readouts for NVS assets and accelerated merchant churn or a prolonged retail slowdown for SHOP; low-probability hits could move shares 20–40% in quarters. Near-term (0–3 months) watch Q/Q revenue trends and holiday e‑commerce cadence; medium-term (3–12 months) FDA decisions and major trial readouts; long-term (1–3 years) hinge on NVS producing 2–3 new $1bn drugs and SHOP maintaining >12% market share.

Trade implications: Tactical: prefer income-weighted exposure to NVS (dividend + buybacks) and growth-exposure to SHOP via time-limited options. Cross-asset: reduce long-duration sovereign bond exposure slightly if funding risk rises from tech re-rating; expect modest rise in equity vols for SHOP around earnings/holiday season and stable-to-lower vols for NVS.

Contrarian angles: Consensus underprices NVS' ability to offset patent cliffs via label expansions — a disciplined 3–5% overweight could outperform if pipeline readouts are benign. Conversely, SHOP’s rally may be priced for flawless SMB recovery; a disciplined scaling-in plan (buy on pullbacks) and volatility-selling around calm prints captures mispricings while guarding against an overbought tech squeeze.

Key Decisions for Investors

• Establish a 2–3% long position in NVS within 1 week for a 6–12 month horizon to collect ~3% yield; enhance yield by selling 1–year covered calls at ~10–15% OTM and place a hard stop-loss at 12% below entry to limit downside from surprise regulatory/patent news.
• Initiate a 1.5–2.5% staged long position in SHOP over the next 3 months: deploy 50% now, add up to 100% of planned size on any pullback of 10–15% from entry or if SHOP misses guidance; hedge 25–40% of exposure by buying a 9–12 month 10–20% OTM put if the stock rallies >25% from current levels.
• Execute a relative-value pair: long SHOP (1.5% portfolio) / short AMZN (0.75% portfolio) for 6–12 months to express platform share gains while partially hedging macro/consumer risk; rebalance if spread widens/narrows by >20%.
• Reduce cyclical retail and small-cap e‑commerce exposure by 2–4% and reallocate into healthcare dividend names (including NVS) if Shopify implied volatility spikes >30% into earnings; reassess after next two quarterly reports (within 3–6 months).